Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
This study found comparable effectiveness between osimertinib and 2<sup>nd</sup> G EGFR-TKIs as first-line treatment for advanced EGFR-mutated NSCLC, with only the NSCLC stage identified as a negative predictor of PFS. However, whether the different second-line treatments affect overall survival should be examined.
Authors
- Chih‐Yen Tu (ORCID: https://orcid.org/0000-0002-8126-6171)
- Hsu-Yuan Chen
- Wei‐Chih Liao (ORCID: https://orcid.org/0000-0001-5362-6953)
- Te‐Chun Hsia (ORCID: https://orcid.org/0000-0003-4297-9918)
- Chia‐Hung Chen (ORCID: https://orcid.org/0000-0003-1158-9722)
- Wen‐Chien Cheng (ORCID: https://orcid.org/0000-0001-8628-6000)
- Hung‐Jen Chen (ORCID: https://orcid.org/0000-0001-6000-9021)
- Yu-Chao Lin (ORCID: https://orcid.org/0000-0002-8241-2898)
Institutions
- National Chung Hsing University (TW)
- China Medical University (TW)
- China Medical University Hospital (TW)
Publication Details
- Journal
- BMC Pulmonary Medicine
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1186/s12890-024-03336-8
- Citations
- 6
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 2.51